Fulcrum Financial Statements From 2010 to 2026

Fulcrum Therapeutics Balance Sheet		Trends
Current Value Last Year Historical Average  10 Year Trend Total Assets 180.2 M 299.8 M 107.1 M Slightly volatile Short and Long Term Debt Total 6.8 M 7.8 M 19.1 M Slightly volatile Other Current Liabilities 6 M 8.8 M 3.9 M Slightly volatile Total Current Liabilities 14.6 M 12.7 M 9 M Slightly volatile Total Stockholder Equity 157.9 M 279.5 M 93.8 M Slightly volatile Other Liabilities 168.4 K 177.3 K 1.8 M Pretty Stable Property Plant And Equipment Net 15.5 M 8.6 M 11.8 M Pretty Stable Accounts Payable 1.3 M 1.3 M 2.1 M Pretty Stable Cash 38.1 M 52.4 M 27.9 M Slightly volatile Non Current Assets Total 13.2 M 12.4 M 8.4 M Slightly volatile Other Assets 3.9 M 3.7 M 1.4 M Slightly volatile Cash And Short Term Investments 162.4 M 277.2 M 95.5 M Slightly volatile Net Receivables 1.9 M 3.8 M 1.2 M Slightly volatile Common Stock Total Equity 62.8 K 59.8 K 23.2 K Slightly volatile Common Stock Shares Outstanding 39.3 M 71.3 M 30.3 M Slightly volatile Liabilities And Stockholders Equity 180.2 M 299.8 M 107.1 M Slightly volatile Non Current Liabilities Total 7.6 M 7.6 M 4.2 M Slightly volatile Capital Surpluse 739 M 703.8 M 257.1 M Slightly volatile Other Current Assets 6.7 M 6.4 M 2.3 M Slightly volatile Other Stockholder Equity 439.6 M 876.6 M 266.4 M Slightly volatile Total Liabilities 22.3 M 20.3 M 13.3 M Slightly volatile Property Plant And Equipment Gross 28.8 M 27.4 M 10.1 M Slightly volatile Total Current Assets 166.9 M 287.4 M 98.7 M Slightly volatile Non Current Liabilities Other 215.2 K 226.6 K 279.9 K Pretty Stable Common Stock 38.1 K 62.1 K 22.6 K Slightly volatile Property Plant Equipment 8.3 M 7.9 M 5.6 M Slightly volatile Current Deferred Revenue 1.2 M 1.3 M 3.2 M Very volatile Capital Stock 43.4 K 62.1 K 30 K Slightly volatile
Fulcrum Therapeutics Income Statement		Trends
Current Value Last Year Historical Average  10 Year Trend Net Interest Income 1.8 M 1.7 M 773.8 K Slightly volatile Interest Income 1.8 M 1.7 M 773.8 K Slightly volatile Depreciation And Amortization 2.1 M 1.8 M 1.4 M Slightly volatile Selling General Administrative 27 M 40.2 M 17.3 M Slightly volatile Other Operating Expenses 90.1 M 117.2 M 60.2 M Slightly volatile Research Development 62.6 M 72.9 M 42.4 M Slightly volatile Cost Of Revenue 76.5 M 72.9 M 22.1 M Slightly volatile Total Operating Expenses 70.9 M 44.3 M 46.6 M Slightly volatile Reconciled Depreciation 2.1 M 1.8 M 1.4 M Slightly volatile Total Other Income Expense Net 14.7 M 14 M 3.6 M Slightly volatile Selling And Marketing Expenses 1.5 M 1.3 M 2 M Slightly volatile
Fulcrum Therapeutics Cash Flow Statement		Trends
Current Value Last Year Historical Average  10 Year Trend Stock Based Compensation 9.5 M 16.7 M 6.2 M Slightly volatile Begin Period Cash Flow 46 M 30.7 M 26.1 M Slightly volatile Other Cashflows From Financing Activities 2.3 M 2.5 M 27.8 M Slightly volatile Depreciation 2.1 M 1.8 M 1.4 M Slightly volatile Capital Expenditures 237.7 K 250.2 K 1.8 M Slightly volatile Total Cash From Financing Activities 3 M 3.2 M 45.9 M Slightly volatile End Period Cash Flow 38.9 M 53.5 M 28.5 M Slightly volatile Change To Netincome 11.9 M 15.4 M 7.6 M Slightly volatile
Financial Ratios		Trends
Current Value Last Year Historical Average  10 Year Trend Price To Sales Ratio 3.11 3.28 36.0005 Very volatile PTB Ratio 1.31 1.38 82.6242 Slightly volatile Days Sales Outstanding 13.04 13.72 100 Slightly volatile Book Value Per Share 3.03 3.53 2.2018 Slightly volatile Stock Based Compensation To Revenue 0.16 0.1819 1.0368 Pretty Stable Capex To Depreciation 0.19 0.2 1.8411 Slightly volatile PB Ratio 1.31 1.38 82.6242 Slightly volatile EV To Sales 2.58 2.72 31.0982 Very volatile Payables Turnover 51.46 49.01 15.5848 Slightly volatile Sales General And Administrative To Revenue 0.37 0.39 2.9935 Pretty Stable Research And Ddevelopement To Revenue 0.68 0.71 6.8902 Very volatile Capex To Revenue 0.0038 0.004 0.1332 Slightly volatile Cash Per Share 3.14 3.5 2.2513 Slightly volatile Days Payables Outstanding 7.32 7.71 451 Slightly volatile Income Quality 0.25 0.26 0.7322 Slightly volatile Current Ratio 21.39 20.37 8.2419 Slightly volatile Tangible Book Value Per Share 3.03 3.53 2.2018 Slightly volatile Receivables Turnover 22.62 21.54 6.8075 Slightly volatile Shareholders Equity Per Share 3.03 3.53 2.2018 Slightly volatile Debt To Equity 0.0388 0.0408 12.3293 Slightly volatile Capex Per Share 0.0049 0.0052 0.0963 Slightly volatile Revenue Per Share 1.22 1.16 0.484 Slightly volatile Interest Debt Per Share 0.15 0.16 1.0331 Slightly volatile Debt To Assets 0.0362 0.0381 3.7661 Slightly volatile Operating Cycle 16.66 17.54 250 Slightly volatile Price Book Value Ratio 1.31 1.38 82.6242 Slightly volatile Days Of Payables Outstanding 7.32 7.71 451 Slightly volatile Ebt Per Ebit 0.49 0.51 0.9211 Slightly volatile Effective Tax Rate 0.0 0.0 0.0 Slightly volatile Company Equity Multiplier 1.57 1.23 2.1905 Slightly volatile Long Term Debt To Capitalization 0.77 0.87 0.9463 Slightly volatile Total Debt To Capitalization 0.0375 0.0394 0.4699 Slightly volatile Debt Equity Ratio 0.0388 0.0408 12.3293 Slightly volatile Quick Ratio 21.39 20.37 8.1033 Slightly volatile Cash Ratio 5.3 6.06 2.9957 Slightly volatile Days Of Sales Outstanding 13.04 13.72 100 Slightly volatile Free Cash Flow Operating Cash Flow Ratio 1.2 1.29 1.1099 Pretty Stable Price To Book Ratio 1.31 1.38 82.6242 Slightly volatile Fixed Asset Turnover 7.89 7.51 2.2664 Slightly volatile Debt Ratio 0.0362 0.0381 3.7661 Slightly volatile Price Sales Ratio 3.11 3.28 36.0005 Very volatile Asset Turnover 0.29 0.28 0.1027 Slightly volatile Price Fair Value 1.31 1.38 82.6242 Slightly volatile

Fulcrum Fundamental Market Drivers

Fulcrum Upcoming Events

About Fulcrum Therapeutics Financial Statements

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Fulcrum Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Fulcrum Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fulcrum Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fulcrum Therapeutics Stock:

How To Invest In Fulcrum Details

Is Fulcrum Stock a good investment? Details

What is Fulcrum Therapeutics' Net Worth? Details

Largest Pharmaceuticals Companies View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies View

Altman Z Score Details

Piotroski F Score Details

Beneish M Score Details

Financial Analysis Details

Buy or Sell Advice Details

Earnings Projections Details